Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Malignant Peripheral Nerve Sheath Tumors are Comprised of Two Epigenetic Subgroups with Distinct Molecular Landscapes, Outcomes and Therapeutic Targets: snRNA Seq Samples

ABSTRACT: Malignant Peripheral Nerve Sheath Tumors are Comprised of Two Epigenetic Subgroups with Distinct Molecular Landscapes, Outcomes and Therapeutic Targets: snRNA Seq Samples

PROVIDER: PRJNA855245 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19962909.fastq.gz	Fastqsanger.gz
	SRR19962910.fastq.gz	Fastqsanger.gz
	SRR19962911.fastq.gz	Fastqsanger.gz
	SRR19962912.fastq.gz	Fastqsanger.gz
	SRR19962913.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 10

Similar Datasets

Malignant Peripheral Nerve Sheath Tumors are Comprised of Two Epigenetic Subgroups with Distinct Molecular Landscapes, Outcomes and Therapeutic Targets: snRNA Seq Samples

Project description:We focused on studying the methylation signature of the spectrum of PNSTs to develop a methylome-based classification of these common tumors. We studied the genome-wide DNA methylation patterns using the Illumina MethylationEPIC array and classified the samples into 5 subgroups. Gene Expression comparing the subgroups were performed using single nuclear RNA Seq

2023-04-03 | GSE207399 | GEO

Malignant Peripheral Nerve Sheath Tumors are Comprised of Two Epigenetic Subgroups with Distinct Molecular Landscapes, Outcomes and Therapeutic Targets: Methylation Samples

Project description:Malignant Peripheral Nerve Sheath Tumors are Comprised of Two Epigenetic Subgroups with Distinct Molecular Landscapes, Outcomes and Therapeutic Targets: Methylation Samples

| PRJNA854154 | ENA

Malignant Peripheral Nerve Sheath Tumors are Comprised of Two Epigenetic Subgroups with Distinct Molecular Landscapes, Outcomes and Therapeutic Targets: Bulk RNA Seq Samples

2023-04-03 | GSE207400 | GEO

Malignant Peripheral Nerve Sheath Tumors are Comprised of Two Epigenetic Subgroups with Distinct Molecular Landscapes, Outcomes and Therapeutic Targets: Bulk RNA Seq Samples

Project description:Malignant Peripheral Nerve Sheath Tumors are Comprised of Two Epigenetic Subgroups with Distinct Molecular Landscapes, Outcomes and Therapeutic Targets: Bulk RNA Seq Samples

| PRJNA855244 | ENA

Malignant Peripheral Nerve Sheath Tumors are Comprised of Two Epigenetic Subgroups with Distinct Molecular Landscapes, Outcomes and Therapeutic Targets: Methylation Samples

2023-04-03 | GSE207207 | GEO

Methylation profiling of malignant peripheral nerve sheath tumour samples

Project description:Methylation profiling of malignant peripheral nerve sheath tumours (MPNSTs), epithelioid MPNSTs, sarcoma NOS, melanomas and spindle cell/sclerosing rhabdomyosarcomas.

2020-07-02 | E-MTAB-8864 | biostudies-arrayexpress

Malignant peripheral nerve sheath tumor (MPNST) tumor samples

Project description:Malignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma. Comprehensive proteomic profiles of 23 MPNST tumor specimens were obtained using LC-MS/MS. Among 23 tumor specimens, 13 patients showed favorable prognosis and 10 did local recurrence/distant metastasis.

2022-12-22 | PXD030585 | JPOST Repository

Comparative genomic hybridization of human malignant peripheral nerve sheath tumors and normal reference DNA

Project description:DNA copy number profiling of malignant peripheral nerve sheath tumours

2009-02-25 | E-MEXP-869 | biostudies-arrayexpress

Distinct immunomodulatory pathways mediate radiotherapy response in malignant peripheral nerve sheath tumors [sgRNA library]

Project description:We performed a genome-wide CRISPRi screen to identify potential contributors to radioresistance in the JH02.2 malignant peripheral nerve sheath tumor (MPNST) cell line.

2025-11-22 | GSE289111 | GEO

Targeting RABL6A-RB1 signaling suppresses malignant peripheral nerve sheath tumors

Project description:Malignant peripheral nerve sheath tumors (MPNSTs) are deadly sarcomas that lack effective therapies. In most MPNSTs, the retinoblastoma (RB1) tumor suppressor is disabled by hyperactivation of cyclin dependent kinases (CDKs), commonly through loss of CDK inhibitory proteins such as p27(Kip1). RABL6A is an inhibitor of RB1 whose role in MPNSTs is unknown. To gain insight into MPNST development and establish new treatment options, we investigated RABL6A-RB1 signaling and CDK inhibitor-based therapy in MPNSTs.

2020-02-11 | GSE145064 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data